Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 10/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.35 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PTAFR | P25105 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4177007 | 0.80 | AR (0.39) | P2RX3MEN1KMT2A | |
| SCHEMBL4169288 | 0.80 | AR (0.39) | P2RX3MEN1KMT2A | |
| SCHEMBL4174159 | 0.80 | AR (0.39) | P2RX3MEN1KMT2A | |
| SCHEMBL4187294 | 0.72 | AR (0.49) | P2RX3MEN1KMT2A | |
| SCHEMBL4187064 | 0.72 | AR (0.49) | P2RX3MEN1KMT2A | |
| SCHEMBL4171499 | 0.69 | AR (0.49) | P2RX3 | |
| SCHEMBL4176624 | 0.68 | P2RX3 (0.34) | P2RX3MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL4174207 | 0.67 | AR (0.36) | P2RX3MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL4022431 | 0.65 | MEN1 (0.44) | P2RX3TGFBR1TGFBR2MEN1KMT2A | |
| SCHEMBL4021549 | 0.63 | MEN1 (0.48) | MEN1KMT2AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | P2RX3 1640/4885TGFBR1 532/4885TGFBR2 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.